Earnings Releases·Nov 12, 2026, 8:05 AM ET

Lucid Diagnostics — Third Quarter 2026 Earnings Summary

Revenue for the nine months ended September 30, 2026, rose to $3.9 million from $3.2 million in the prior year period, while Q3 revenue remained flat at $1.2 million; GAAP net loss narrowed to $6.7 million ($0.03 per share) from $10.4 million ($0.10 per share) in the prior year, though cash reserves declined to $18.0 million from $34.7 million at year-end 2025.
Medicare reimbursement for EsoGuard commenced in October at $1,938.01 per test, driving Q3 volume to 2,871 tests and a record October volume exceeding 1,800, with management projecting five Concert client health plans to adopt coverage policies by year-end.
The company strengthened its balance sheet with a $15.0 million Series C Convertible Preferred Stock private placement closing subsequent to the quarter, while management shifts focus from external reimbursement constraints to commercial acceleration and operational execution.
Future growth outlook remains tied to the resolution of the pending MolDX LCD reconsideration and the anticipated expansion of VA programs, with CEO commentary characterizing the current phase as a transition from a "marathon" to a "sprint" for revenue realization.